CRL Stock Chart & Stats
$3960.00
$100.00(2.59%)
At close: 4:00 PM EDT
$3960.00
$100.00(2.59%)
Day’s Range― - ―
52-Week Range$3,132.64 - $4,066.92
Previous CloseN/A
Volume26.00
Average Volume (3M)2.00
Market Cap
$201.98B
Enterprise Value$10.71K
Total Cash (Recent Filing)$191.83M
Total Debt (Recent Filing)$3.06B
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Aug 05, 2026EPS Estimate
47.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding48,167,730
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.19
Price to Sales (P/S)2.51
P/FCF Ratio19.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,024.90Price Target Upside1.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $3132.64 and its highest was $4066.92 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Charles River Laboratories Intl’s market cap is $201.98B.
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Aug 05, 2026 which is in 6 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on May 07, 2026. The company reported $35.927 earnings per share for the quarter, beating the consensus estimate of $33.904 by $2.023.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is 47.75.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 48,167,730 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $35.927 in its last earnings report, beating expectations of $33.904. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Currently, no hedge funds are holding shares in MX:CRL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charles River Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,024.90 (1.64% Upside)
$4,024.90 (1.64% Upside)
Blogger Sentiment
Neutral
MX:CRL Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.95%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL Company Deck
CRL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: near-term operational and margin headwinds (Q1 organic revenue decline, margin compression, negative free cash flow in the quarter and segment-specific pressures in RMS and DSA) were weighed against clear strategic actions and forward-looking levers (acquisitions to secure NHP supply and expand NAMs, completed divestitures, $100M incremental cost savings in 2026, $300M+ cumulative savings, strong bookings/net book-to-bill and a $200M share repurchase). Management reaffirmed FY guidance for organic revenue and EPS, expects meaningful margin expansion in the second half, and signaled improving demand/proposal trends—resulting in a mix of near-term softness but constructive medium-term outlook.View all MX:CRL earnings summariesCRL Revenue Breakdown
21.07% RMS
59.84% DSA
19.09% Manufacturing

CRL Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$4,024.90
▲(1.64% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










